Interleukin: A Literature Course

How this course is organised

This course walks through the published interleukin literature in six modules: what an interleukin is, how mechanism has been described, what individual studies reported, what the literature says about harm, what pharmacokinetic information exists, and how interleukin-related products are regulated. Each module closes with the limits of that evidence. Nothing here is a protocol, and no dose is described, because the papers cited below are mechanism, marker and review papers rather than human dosing trials. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or treatment decision.

Module 1: What an interleukin is and how it has been studied

The term interleukin describes a class of small, secreted signalling proteins — cytokines — that were originally named for signalling “between leukocytes.” They are numbered in order of discovery (interleukin-1, interleukin-2, and so on), and each number often covers a family of related proteins with shared receptors rather than a single molecule. They are not synthetic research peptides; they are endogenous proteins encoded in the genome, produced by immune cells and by non-immune tissue cells, and studied both as native proteins and as engineered laboratory constructs.

Class and family structure

A 2026 review in Neural Regeneration Research traced the interleukin-17 family from its evolutionary origin through its receptor biology to its clinical implications across immune diseases, presenting it as a multi-member family rather than one protein (PMID 40536951). A French-language review published in La Revue de Médecine Interne covered interleukin-1 together with the inflammasome and the autoinflammatory diseases linked to that axis, illustrating how one interleukin family is framed around an upstream activation complex (PMID 27639913).

Forms: precursor, mature and engineered

Several interleukins exist first as precursor proteins. Researchers using proximity labelling reported evolutionarily conserved nuclear interactions for pro-interleukin-1α, indicating that the precursor form has binding partners inside the nucleus in addition to the extracellular signalling role of the released protein (PMID 39117622). Interleukins have also been re-engineered in the laboratory: a 2020 paper in Immunology and Cell Biology described a decoy-resistant interleukin-18 variant designed to evade its natural decoy binding protein and reported cancer-killing activity for that engineered form (PMID 32535941).

How the field studies them

• Serum marker studies — measuring circulating interleukin concentrations in patients versus controls, as in a study of serum interleukin-6, interleukin-17A and tumour necrosis factor-alpha in recurrent aphthous stomatitis (PMID 33432616).
• Animal and tissue models — such as work on neutrophil-derived interleukin-17A in neuroinflammation after traumatic brain injury (PMID 36254991).
• Autoantibody studies — a 2024 New England Journal of Medicine report examined anti-interleukin-23 autoantibodies in adult-onset immunodeficiency, effectively studying what happens when one interleukin is neutralised in humans by their own antibodies (PMID 38507753).
• Medicinal chemistry — a 2018 study in European Journal of Medicinal Chemistry identified fused pyrimidines as inhibitors of interleukin-17 secretion (PMID 29909341).

Limits of the evidence (Module 1)

“Interleukin” is a category, not a compound. Findings about interleukin-17 do not transfer to interleukin-6 or interleukin-18, and the papers above cover different families, different species and different questions. None of them defines a single entity that could be described with one mechanism or one safety profile.

Module 2: Mechanism as described in the literature

Across the cited work, interleukins are described as receptor-binding messengers whose output depends on which cells release them, which cells carry the receptor, and when in the course of a disease the signal arrives.

Upstream control: the inflammasome

The interleukin-1 family is tied to inflammasome activation, and a review of interleukin-1, the inflammasome and autoinflammatory diseases described this pathway as the organising mechanism behind that group of conditions (PMID 27639913). Mechanistic detail has also been added inside the cell: researchers reported that pro-interleukin-1α engages conserved nuclear interaction partners, a role distinct from receptor signalling outside the cell (PMID 39117622).

Downstream effects on tissue and vasculature

A 2017 study in the Journal of Cerebral Blood Flow and Metabolism examined the effects of interleukin-1β on cortical spreading depolarization and on cerebral vasculature, linking a single interleukin to both neuronal and vascular responses (PMID 27037093). In injury settings, the study of neutrophil-derived interleukin-17A reported that this cell source participates in neuroinflammation induced by traumatic brain injury (PMID 36254991).

Context and timing

A 2025 commentary in Immunity, titled “Interleukin-17 and fat: Timing is everything,” framed interleukin-17 activity in adipose tissue as time-dependent rather than uniformly pro- or anti-inflammatory (PMID 39813991). The broader interleukin-17 family review similarly connected receptor biology to a range of immune disease outcomes rather than to a single effect (PMID 40536951).

Pathway interruption

Two lines of work describe what happens when interleukin signalling is blocked. Chemically, fused pyrimidine compounds were identified as inhibitors of interleukin-17 secretion (PMID 29909341). Immunologically, the 2024 report on anti-interleukin-23 autoantibodies described neutralisation of an interleukin by a patient's own antibodies in the setting of adult-onset immunodeficiency (PMID 38507753).

Limits of the evidence (Module 2)

Mechanistic descriptions come largely from cell systems, animal models and reviews. Association between an interleukin and a disease process in a model does not establish that the same relationship drives the disease in humans, and none of these papers reported a dosing regimen for an administered interleukin in people.

Module 3: Reported outcomes by study

The table summarises what each cited study or review examined and what it reported, with no extrapolation beyond the published scope.

Limits of the evidence (Module 3)

Marker studies such as the recurrent aphthous stomatitis serum analysis are cross-sectional in design and describe association, not causation (PMID 33432616). Reviews and commentaries summarise other people's data rather than generating new outcomes (PMID 31827374). No paper in this set reported a controlled clinical endpoint after administering an interleukin to healthy people.

Module 4: Interleukin Side Effects: What Studies Report

None of the verified papers was a safety or tolerability trial of an administered interleukin product in humans, so there are no adverse-event rates, discontinuation figures or laboratory abnormality tables to summarise. What the literature does report is harm-associated biology — situations in which interleukin activity, or its loss, coincided with pathology.

• Loss of an interleukin signal in humans. The 2024 New England Journal of Medicine report described anti-interleukin-23 autoantibodies in adult-onset immunodeficiency, that is, a clinical immunodeficiency state occurring alongside neutralisation of interleukin-23 (PMID 38507753).
• Interleukin-1 and autoinflammation. A review of interleukin-1, the inflammasome and autoinflammatory diseases framed excessive interleukin-1 pathway activity as central to that disease group (PMID 27639913).
• Neurovascular effects. Researchers reported effects of interleukin-1β on cortical spreading depolarization and cerebral vasculature, a set of responses studied in the context of brain injury and headache biology (PMID 27037093).
• Injury-driven inflammation. The traumatic brain injury study reported that neutrophil-derived interleukin-17A participates in neuroinflammation after injury (PMID 36254991).
• Disease-associated elevation. Serum interleukin-6 and interleukin-17A were measured alongside tumour necrosis factor-alpha in patients with recurrent aphthous stomatitis (PMID 33432616).

Limits of the evidence (Module 4)

Harm-associated biology is not the same as a product side-effect profile. The autoantibody findings describe a spontaneous human condition rather than a drug exposure (PMID 38507753), and the neurovascular and brain-injury work used experimental models (PMID 27037093, PMID 36254991). Anyone seeking an adverse-event profile for a licensed interleukin-targeting medicine would need that product's own regulatory labelling, which is outside this evidence set.

Module 5: Pharmacokinetics where data exist

Pharmacokinetic data are the weakest part of this evidence set. None of the verified papers reported half-life, maximum concentration, clearance, bioavailability or volume of distribution for an interleukin in humans, and no route of administration was characterised quantitatively.

Two papers touch on disposition-adjacent biology. The decoy-resistant interleukin-18 work described an engineered protein built to escape its natural decoy receptor, a design question about how much active signal survives in the biological environment rather than a plasma-concentration measurement (PMID 32535941). The proximity-labelling study of pro-interleukin-1α addressed subcellular localisation and nuclear binding partners, which is distribution at the level of the cell rather than the body (PMID 39117622).

Limits of the evidence (Module 5)

Because no pharmacokinetic parameters appear in these papers, no timing, frequency or exposure statement can be supported from them. Readers comparing interleukin-based biologics should look to regulatory product documents, which report those parameters product by product.

Module 6: Regulatory status, stated factually

Interleukins occupy several distinct regulatory categories at once, and the category matters more than the molecule name.

1. Approved medicines. Some recombinant interleukin proteins and many monoclonal antibodies that block interleukin pathways have been reviewed and approved by national regulators such as the US Food and Drug Administration and the European Medicines Agency for specific indications. Each approval is tied to a named product, a manufacturing standard, an indication and an approved label; approval of one interleukin-targeting antibody says nothing about the status of any other interleukin preparation.
2. Research use only (RUO) material. Recombinant interleukins sold to laboratories are supplied as research reagents. RUO labelling means the material has not been evaluated for safety, purity or potency for human use and is not authorised for administration to people or animals outside an approved research protocol.
3. Compounding. In the United States, pharmacy compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act is limited to substances that meet defined eligibility criteria; complex recombinant biologics are generally licensed under the biologics framework rather than compounded, and eligibility lists change over time.
4. Clinical research. Investigational interleukin constructs, including engineered variants of the kind described for decoy-resistant interleukin-18, move forward only under regulated trial authorisations (PMID 32535941).

This section describes general regulatory categories and is not legal advice; rules differ by country and state and change over time.

Limits of the evidence (Module 6)

The verified papers are scientific studies, not regulatory documents, so they do not establish approval status for any product. Regulatory classification must be verified against current agency records rather than inferred from published research.

What the studies did not test

Reading the set as a whole, several questions remain unaddressed:

• Healthy-population use. No cited study administered an interleukin to healthy volunteers or reported outcomes in people without disease.
• Dose-response. No paper in this set reported a dose, a schedule or an exposure range that could be described here.
• Long-term follow-up. The autoantibody report and the marker study describe cross-sectional clinical observations rather than multi-year outcome tracking (PMID 38507753, PMID 33432616).
• Head-to-head comparison. The interleukin-17 family review and the interleukin-6 psoriasis review summarised separate literatures and did not compare interleukin targets against one another in a single trial (PMID 40536951, PMID 29724321).
• Translation from model to human. The chronic-wound and adipose-tissue discussions were framed as potential targets and mechanistic hypotheses, not as demonstrated clinical outcomes (PMID 31827374, PMID 39813991).

The honest summary is that interleukin biology is deeply mapped at the level of pathways and disease association, while product-level questions — exposure, safety in specific populations, comparative benefit — are answered only within the regulatory dossiers of individual approved medicines, not by this literature.

References

• Cancer-killing, decoy-resistant interleukin-18 (Immunology and Cell Biology, 2020)
• Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency (The New England Journal of Medicine, 2024)
• Interleukin-17 family in health and immune diseases: From origin to clinical implications (Neural Regeneration Research, 2026)
• Effects of interleukin-1β on cortical spreading depolarization and cerebral vasculature (Journal of Cerebral Blood Flow and Metabolism, 2017)
• Proximity labelling of pro-interleukin-1α reveals evolutionary conserved nuclear interactions (Nature Communications, 2024)
• Serum interleukin-6, interleukin-17A, and tumor necrosis factor-alpha in patients with recurrent aphthous stomatitis (Journal of Oral Pathology & Medicine, 2021)
• Interleukin-17: Potential Target for Chronic Wounds (Mediators of Inflammation, 2019)
• Neutrophil-derived interleukin-17A participates in neuroinflammation induced by traumatic brain injury (Neural Regeneration Research, 2023)
• Identification of fused pyrimidines as interleukin 17 secretion inhibitors (European Journal of Medicinal Chemistry, 2018)
• Interleukin-1, inflammasome and autoinflammatory diseases (La Revue de Médecine Interne, 2018)
• Interleukin-17 and fat: Timing is everything (Immunity, 2025)
• Interleukin-6 in Psoriasis (Acta Academiae Medicinae Sinicae, 2018)